Monday - Friday - 7:30am - 6:00pm   /   Lunes - Viernes - 7:30am - 6:00pm

Fundacion's Publications

  • Maribel Rodriguez-Torres, MD, CPI
    Founder and Medical Director
    Internal Medicine, Gastroenterology

    “Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks”. Rodriguez-Torres M, Govindarajan S, Diago M, et al. Liver International (In press).

    “Chronic Hepatitis C in the Latino population (Review article)”. Rodriguez-Torres M. Current Hepatitis Reports (In press).

    “Improved Outcomes in HCV Patients with Difficult to Treat Characteristics: Randomized Study of Intensified Peginterferon α-2a/Ribavirin”. Michael W Fried, Donald Jensen, Maribel Rodriguez-Torres, Lisa Nyberg, et al. Hepatology (In Press).

    “Antiviral effects and safety of Telaprevir, Peginterferon Alfa-2a and Ribavirin for 28 days in hepatitis c patients”. Lawitz E, Rodriguez-Torres M, Muir A, Kieffer T. J Hepatol. 2008 Aug;49(2):163-9. Epub 2008 Apr 29.

    “Weight affect relapse rates in Latinos with genotype 2/3 Chronic Hepatitis C (CHC)  treated with Peg IFN Alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of Ribavirin for 24 weeks”. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G et al. J Med Virol. 2008 Jul 22;80(9):1576-1580. [Epub ahead of print].

    “R 1626 plus peginterferon alfa 2-a provides robust supression of HCV RNA ans significant sinergy with Ribavirin”. PJ Pockros, D Nelson, E Godofsky, M Rodriguez-Torres, et al. Hepatology. 2008 Jun 20. [Epub ahead of print].

    “Latinos and Chronic Hepatitis C: A singular population (Review article)”. Rodriguez-Torres M. Clin Gastroenterol Hepatol. 2008 May;6(5):484-90.

    “Hepatic Steatosis in HCV/HIV Co-Infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study”. Rodríguez-Torres M, Govindarajan S, Sola R, et al. J Hepatol. 2008 May;48(5):756-64. Epub 2008 Feb 7.

    “Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis”. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara AM, Jiménez-Rivera J. Ann Hepatol. 2008 Jan-Mar;7(1):72-7.

    “Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C”. McHutchison J, Dusheiko G, Shiffman M, Rodriguez-Torres M, Sigal S. N Engl J Med. 2007 Nov 29;357(22):2227-36.

    “Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection”. Dore GJ, Torriani FJ, Rodriguez-Torres M, et al. AIDS. 2007 Jul 31;21(12):1555-9.

    “Occult hepatitis B virus infection in the setting of Hepatitis C virus (HCV) and Human Immunodeficiency virus (HIV) coinfection: clinically relevant or a diagnostic problem?”.Maribel Rodríguez-Torres, Juan Gonzalez-Garcia, Norbert Bräu, Ricardo Solá, Santiago Moreno, Giuseppe Paraninfo, Jürgen Rockstroh, Fiona Smaill, Mendes-Correa Maria, Jean DePamphilis, and Francesca J. Torriani for the APRICOT investigators. J Med Virol. 2007 Jun;79(6):694-700.

    “Effect of hepatitis C virus (HCV) treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus (HIV): A paired liver biopsy study”. Maribel Rodríguez-Torres, Jose F. Rodríguez-Orengo, Carlos F. Ríos-Bedoya, Alberto Fernández-Carbia, Acisclo M. Marxuach-Cuétara, Abimael Lo´pez-Torres and Josselyn Jiménez-Rivera. Journal of Hepatology. Volume 46, Issue 4, April 2007, Pages 613-619.

    “Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis”. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindollar R, Rodriguez-Torres M, et al. Hepatology. 2007 Feb 26;45(3):569-578.

    “Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy”. Rodriguez-Torres M, Rodriguez-Orengo J, Rios-Bedoya C, et al.J Clin Virol. 2007 Jan;38(1):32-8. Epub 2006 Oct 24.

    “Treatment of Hepatitis C Virus Infection in Drug Addicts”. Rodriguez-Torres M. Annals of Hepatology. 2006:5(Suppl 1):S60-S62.

    “Cost-effectiveness of Peginterferon alfa-2a (40KD) plus Ribavirin in Patients with HIV and hepatitis C virus co-infection”.John Hornberger, Francesca Torriani, Douglas Dieterich, Norbert Bräu, Mark Sulkowski, Maribel Rodriguez Torres, Jesse Green, Kavita Patel. J Clin Virol. 2006 Aug;36(4):283-91. Epub 2006 Jun 9).

    “Chronic Hepatitis C in Patients with Persistently ‘Normal’ Alanine Aminotransferase Levels”. Mitchell Shiffman, Moisés Diago, Albert Tran, Paul Pockros, Robert Reindollar, Daniele Prati, Maribel Rodríguez-Torres, Pilar Lardelli, Steven Blotner, and Stefan Zeuzem. Clin Gastroenterol Hepatol. 2006 May;4(5):645-52.

    “Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy”.  Norbert Braü, Mirella Salvatore, Carlos F. Ríos-Bedoya, Alberto Fernandéz-Carbia, Fiorenzo Paronetto, José F. Rodríguez-Orengo, Maribel Rodríguez-Torres. J of Hepatology. 44 (2006) 47-55.

    “A 1-Year trial of Telbivudine, Lamivudine, and the combination in patients with hepatitis B e Antigen-Positive chronic hepatitis B”. Ching-Lung Lai, Nancy Leung, Eng-Kiong Teo, Myron Tong, Florence Wong, Hie-Won Hann, Steven Han, Thierry Poynard, Maureen Myers, George Chao, Deborah Lloyd, Nathaniel A. Brown, and the Telbivudine Phase II Investigator Group. Gastroenterology, August 2005, Vol. 129:2.

    “Progression to cirrhosis in Latinos with chronic hepatitis C: high risk in Puerto Ricans with and without HIV coinfection”. Maribel Rodríguez-Torres, Carlos F. Ríos-Bedoya, José Rodríguez-Orengo, Alberto Fernández-Carbia, Acisclo M. Marxuach-Cuétara, Abimael López-Torres, Rosa Salgado-Mercado and Norbert Bräu. J Clin Gastroenterol. 2006 Apr;40(4):358-66.

    “Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with HIV-HCV Co-infection: Results of a Randomized Clinical Study”. M. Rodriguez-Torres, F. J. Torriani, V. Soriano, M.J. Borucki, P. Piliero, E. Lissen, M. Sulkowski, D. Dieterich, K Wang, J.-M. Gries, D. Back for the APRICOT Study Group. Antimicrob Agents Chemother. 2005 Oct;49(10):3997-4008.

    “Double blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients”. Rodríguez-Torres M, Rodríguez-Orengo J, Ríos-Bedoya C, Fernández-Carbia A, Salgado-Mercado R, Marxuach-Cuétara A. Dig Dis and Sci 2006 Jan;51(1):161-7.

    “High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin”. Rodríguez-Torres M, Rodríguez-Orengo J, Ríos-Bedoya C, Salgado-Mercado R, Aponte-Rivera E, Marxuach-Cuétara A, , Fernández-Carbia A. Dig Dis Sci. 2005 Apr;50(4):634-9.

    “Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection in HCV/HIV Co-infection”.  Torriani F, Rodríguez-Torres M, Rockstroh J, et al.  N Engl J Med. 2004 Jul 29;351(5):438-50.

    “Treatment of chronic hepatitis C in HIV/HCV-coinfected patients with interferon alfa-2b plus full-course versus 16-week delayed ribavirin”,  Brau N, Rodríguez-Torres M, Prokupek D, Bonacini M, Giffen C, Smith J, Frost K, Kostman J. Hepatology 2004;39:989-998.

    “Racial Differences in Response Rates to Induction Therapy Followed by Every Other Day Dosing with Consensus Interferon (Interferon Alfacon-1) for HCV Infected Patients Naïve to Previous Therapy”.  Gaglios, Rodríguez-Torres, Herring, Anand, Box, et.al. J  Clin Gastroenterol, 38:7:599-604, August 2004.

    “The co-infected generation: Hepatitis C and HIV co-infection”. Rodríguez-Torres. Advances in Hepatitis C; 2001, Volume 1, Issue 5, Pages 7-9.

    “Interferon alfa 2b treatment for HCV in HIV co-infection with active protease inhibitors”. Rodríguez-Torres. World Congress of AIDS, Geneva, 1998.

    Grisell Ortiz-Lasanta, MD
    Associate Director
    Internal Medicine

    Email:This email address is being protected from spambots. You need JavaScript enabled to view it.

    “Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis”. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara AM, Jiménez-Rivera J. Ann Hepatol. 2008 Jan-Mar;7(1):72-7.

    “Weight affect relapse rates in Latinos with genotype 2/3 Chronic Hepatitis C (CHC)  treated with Peg IFN Alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of Ribavirin for 24 weeks”. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G et al. J Med Virol. 2008 Jul 22;80(9):1576-1580. [Epub ahead of print].

    Acisclo M. Marxuach-Cuetara, MD
    Internal Medicine, Gastroenterology
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    “High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin”. Dig Dis Sci. 2005 Apr;50(4):634-9. Rodríguez-Torres M, Rodríguez-Orengo J, Ríos-Bedoya C, Salgado-Mercado R, Aponte-Rivera E, Marxuach-Cuétara A, Fernández-Carbia A.

    “Progression to cirrhosis in Latinos with chronic hepatitis C: high risk in Puerto Ricans with and without HIV coinfection”. Journal of Clinical Gastroenterology (In press). Maribel Rodríguez-Torres, Carlos F. Ríos-Bedoya, José Rodríguez-Orengo, Alberto Fernández-Carbia, Acisclo M. Marxuach-Cuétara, Abimael López-Torres, Rosa Salgado-Mercado and Norbert Bräu.

    “Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy”. Rodriguez-Torres M, Rodriguez-Orengo J, Rios-Bedoya C, Marxuach-Cuétara A, et al.J Clin Virol. 2007 Jan;38(1):32-8. Epub 2006 Oct 24.

    “Effect of hepatitis C virus (HCV) treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus (HIV): A paired liver biopsy study”. Maribel Rodríguez-Torres, Jose F. Rodríguez-Orengo, Carlos F. Ríos-Bedoya, Alberto Fernández-Carbia, Acisclo M. Marxuach-Cuétara, Abimael Lo´pez-Torres and Josselyn Jiménez-Rivera.Journal of Hepatology. Volume 46, Issue 4, April 2007, Pages 613-619.

    “Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis”. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara AM, Jiménez-Rivera J. Ann Hepatol. 2008 Jan-Mar;7(1):72-7.

    “Weight affect relapse rates in Latinos with genotype 2/3 Chronic Hepatitis C (CHC)  treated with Peg IFN Alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of Ribavirin for 24 weeks”. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara A et al. J Med Virol. 2008 Jul 22;80(9):1576-1580. [Epub ahead of print].

    Rafael D. Betancourt-Garcia, MD
    Internal Medicine, Hematology-Medical Oncology
    Email:This email address is being protected from spambots. You need JavaScript enabled to view it.

    Betancourt-García RD, Castro J, Fernández AC, López-Enríquez A, Fradera J, Pacheco E.  “Acquired Acute Myelogenous Leukemia after Therapy for Acute Promyelocytic

    Leukemia with t(15;17):  a Case Report and Review of the Literature”.  PRHSJ June 2009; 28; 2: 146-150

    Betancourt-García RD, García-Pallas MV, Pacheco E, Castro J, Cabanillas F.  REVIEW ARTICLE   “Diffuse Large-Cell Lymphoma Part I:  Clinical Features, Histology, and Prognosis.  PRHSJ March 2009; 28; 1:  5-11

    García-Pallas MV, Betancourt-García RD, Pacheco E, Castro J, Cabanillas F.  REVIEW ARTICLE  “Diffuse Large-Cell Lymphoma Part II:  Management.  PRHSJ March 2009; 28; 1:  12-17

     

 

Who We Are?

Located in San Juan, Puerto Rico, Fundación de Investigación (FDI) is a clinical research center with state-of-the-art facilities that comprise medical treatment for multiple conditions, a 30-bed phase I unit, an in-house bioanalytical laboratory, multispecialty experienced personnel, and the latest in medical technology. We are also an active medical care facility for patients with diverse medical ailments.

Executive Leadership

Dr. Jose F. Rodriguez-Orengo
Chief Executive Offcicer - CEO,
Chief Scientific Officer & BioLab Director


Grisell Ortíz-Lasanta, MD
Associate Director

Mirelis Acosta, MD
Chief Medical Officer

Michelle Echeandia
Chief Operating Officer

Our partners

Gilead Pharmaceuticals
Amgen
Astra Zeneca
Bristol Myers Squibb
GlaxoSmithKline
Merck Sharp
Novartis Pharmaceuticals
Pfizer
Sanofi-aventis
Jansen Pharmaceuticals

Where to find us?

Address
Fundación de Investigación
998 Muñoz Rivera Ave.
San Juan, PR 00927

Phone Number
Tel. (787) 722-1248
Fax. (787) 721-6098